The promising results of these clinical trials suggest that AMG510 is an effective drug for treating KRAS G12C NSCLC patients, and that possible combinations of sotorasib with other anticancer drugs should be tested to determine their safety [54]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.